Martin Biström
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Martin Biström has a total of 38 co-authors. Here are the top co-authors by number of shared publications:
Magnus Vrethem
Department of Neurology and Department of Biomedical and Clinical Sciences (BKV), Linköping University, Linköping, Sweden
7 shared publicationsMartin Gunnarsson
Department of Neurology, Faculty of Medicine and Health, Örebro University, Örebro, Sweden
7 shared publicationsOluf Andersen
Department of Clinical Neuroscience, Institute of Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
6 shared publicationsPeter Sundström
Department of Clinical Sciences, Neurosciences Umeå University Umeå Sweden
6 shared publications- Viktor Grut
Department of Clinical Sciences, Neurosciences Umeå University Umeå Sweden
6 shared publications Daniel Jons
Department of Clinical Neuroscience, Institute of Neuroscience and Physiology, Sahlgrenska Academy University of Gothenburg Gothenburg Sweden
5 shared publications
Latest Publications
- Open Access
- 16 April 2026
- Published by Wiley in Clinical & Translational Immunology
- Vol. 15 (4) , e70094
Seropositivity against rubella virus envelope protein 1, but not 2, is associated with an increased risk of multiple sclerosis
Objective: Several factors have been associated with altered risk of developing multiple sclerosis (MS). Epstein–Barr virus (EBV) is the critical risk factor for MS, but recent studies indicate that human herpesvirus 6A (HHV‐6A) and cytomegalovirus (CMV) are involved in MS aetiopathogenesis. We recently reported an association between rubella virus (RV) envelope protein 1 (E1) seropositivity and the risk of developing MS. Here, we aimed to further explore this association. Methods: Bio‐banked blood samples collected before the onset of MS from 981 cases and 1278 matched controls were analysed for antibodies against RV envelope proteins 1 and 2 (E2), and serum‐neurofilament light chain (S‐NfL), a marker for axonal injury. The association between RV and MS was analysed with conditional logistic regression, calculating odds ratios (OR) with 95% confidence intervals (CI). Results: Rubella E1 seropositivity was significantly associated with a higher risk of MS development, even when adjusting for EBV, CMV and HHV‐6A serostatus (OR = 1.67, 95% CI 1.29–2.14, P < 0.001). We also observed an increase in seroreactivity against RV E1 before an increase in S‐NfL in MS cases, indicating that increased RV E1 seroreactivity precedes axonal injury in the MS prodrome at group‐level. There was no association between RV E2 serostatus and MS risk. The association between RV E1 serostatus and MS risk remained similar when the analysis was restricted to unvaccinated participants (OR = 1.78, 95% CI 1.07–2.98, P = 0.028). Conclusions: Our results support a broadening of the viral hypothesis in MS, arguing for further studies on the neurotropic RV in MS aetiology.
- 16 April 2026
- Published by Wiley in Clinical & Translational Immunology
- Vol. 15 (4) , e70094
Open AccessSeropositivity against rubella virus envelope protein 1, but not 2, is associated with an increased risk of multiple sclerosis
Objective: Several factors have been associated with altered risk of developing multiple sclerosis (MS). Epstein–Barr virus (EBV) is the critical risk factor for MS, but recent studies indicate that human herpesvirus 6A (HHV‐6A) and cytomegalovirus (CMV) are involved in MS aetiopathogenesis. We recently reported an association between rubella virus (RV) envelope protein 1 (E1) seropositivity and the risk of developing MS. Here, we aimed to further explore this association. Methods: Bio‐banked blood samples collected before the onset of MS from 981 cases and 1278 matched controls were analysed for antibodies against RV envelope proteins 1 and 2 (E2), and serum‐neurofilament light chain (S‐NfL), a marker for axonal injury. The association between RV and MS was analysed with conditional logistic regression, calculating odds ratios (OR) with 95% confidence intervals (CI). Results: Rubella E1 seropositivity was significantly associated with a higher risk of MS development, even when adjusting for EBV, CMV and HHV‐6A serostatus (OR = 1.67, 95% CI 1.29–2.14, P < 0.001). We also observed an increase in seroreactivity against RV E1 before an increase in S‐NfL in MS cases, indicating that increased RV E1 seroreactivity precedes axonal injury in the MS prodrome at group‐level. There was no association between RV E2 serostatus and MS risk. The association between RV E1 serostatus and MS risk remained similar when the analysis was restricted to unvaccinated participants (OR = 1.78, 95% CI 1.07–2.98, P = 0.028). Conclusions: Our results support a broadening of the viral hypothesis in MS, arguing for further studies on the neurotropic RV in MS aetiology.
- Open Access
- 18 July 2024
- Published by Wiley in European Journal of Neurology
- Vol. 31 (10) , e16387
Rubella virus seropositivity after infection or vaccination as a risk factor for multiple sclerosis
Background: Multiple sclerosis (MS) is a demyelinating disease affecting millions of people worldwide. Hereditary susceptibility and environmental factors contribute to disease risk. Infection with Epstein–Barr virus (EBV) and human herpesvirus 6A (HHV‐6A) have previously been associated with MS risk. Other neurotropic viruses, such as rubella virus (RV), are possible candidates in MS aetiopathogenesis, but previous results are limited and conflicting.Methods: In this nested case–control study of biobank samples in a Swedish cohort, we analysed the serological response towards RV before the clinical onset of MS with a bead‐based multiplex assay in subjects vaccinated and unvaccinated towards RV. The association between RV seropositivity and MS risk was analysed with conditional logistic regression.Results: Seropositivity towards RV was associated with an increased risk of MS for unvaccinated subjects, even when adjusting for plausible confounders including EBV, HHV‐6A, cytomegalovirus and vitamin D (adjusted odds ratio [AOR] = 4.0, 95% confidence interval [CI] 1.8–8.8). Cases also had stronger antibody reactivity towards rubella than controls, which was not seen for other neurotropic viruses such as herpes simplex or varicella zoster. Furthermore, we observed an association between RV seropositivity and MS in vaccinated subjects. However, this association was not significant when adjusting for the aforementioned confounders (AOR = 1.7, 95% CI 1.0–2.9).Conclusions: To our knowledge, these are the first reported associations between early RV seropositivity and later MS development. This suggests a broadening of the virus hypothesis in MS aetiology, where molecular mimicry between rubella epitopes and human central nervous system molecules could be an attractive possible mechanism.
- 18 July 2024
- Published by Wiley in European Journal of Neurology
- Vol. 31 (10) , e16387
Open AccessRubella virus seropositivity after infection or vaccination as a risk factor for multiple sclerosis
Background: Multiple sclerosis (MS) is a demyelinating disease affecting millions of people worldwide. Hereditary susceptibility and environmental factors contribute to disease risk. Infection with Epstein–Barr virus (EBV) and human herpesvirus 6A (HHV‐6A) have previously been associated with MS risk. Other neurotropic viruses, such as rubella virus (RV), are possible candidates in MS aetiopathogenesis, but previous results are limited and conflicting.Methods: In this nested case–control study of biobank samples in a Swedish cohort, we analysed the serological response towards RV before the clinical onset of MS with a bead‐based multiplex assay in subjects vaccinated and unvaccinated towards RV. The association between RV seropositivity and MS risk was analysed with conditional logistic regression.Results: Seropositivity towards RV was associated with an increased risk of MS for unvaccinated subjects, even when adjusting for plausible confounders including EBV, HHV‐6A, cytomegalovirus and vitamin D (adjusted odds ratio [AOR] = 4.0, 95% confidence interval [CI] 1.8–8.8). Cases also had stronger antibody reactivity towards rubella than controls, which was not seen for other neurotropic viruses such as herpes simplex or varicella zoster. Furthermore, we observed an association between RV seropositivity and MS in vaccinated subjects. However, this association was not significant when adjusting for the aforementioned confounders (AOR = 1.7, 95% CI 1.0–2.9).Conclusions: To our knowledge, these are the first reported associations between early RV seropositivity and later MS development. This suggests a broadening of the virus hypothesis in MS aetiology, where molecular mimicry between rubella epitopes and human central nervous system molecules could be an attractive possible mechanism.
- Open Access
- 11 June 2024
- Published by Wiley in Annals of Neurology
- Vol. 96 (2) , 302-305
Interactions between High Seroreactivity to Human Herpes Virus 6A and Epstein–Barr Virus in MS Development: A Presymptomatic Case–Control Study
Synergistic interactions between human herpesvirus 6A (HHV‐6A) and Epstein–Barr virus (EBV) are hypothesized in the etiopathogenesis of multiple sclerosis (MS). This study investigated if HHV‐6A and EBV seroreactivities interact regarding the risk of developing MS. Antibodies against viral antigens were analyzed in biobank samples from 670 individuals who later developed MS and matched controls. Additive interactions were analyzed. A significant interaction between HHV‐6A and EBNA‐1 seroreactivities was observed in study participants above the median age of 24.9 years (attributable proportion due to interaction = 0.45). This finding supports the hypothesis that HHV‐6A and EBV infections interact in MS development. ANN NEUROL 2024;96:302–305
- 11 June 2024
- Published by Wiley in Annals of Neurology
- Vol. 96 (2) , 302-305
Open AccessInteractions between High Seroreactivity to Human Herpes Virus 6A and Epstein–Barr Virus in MS Development: A Presymptomatic Case–Control Study
Synergistic interactions between human herpesvirus 6A (HHV‐6A) and Epstein–Barr virus (EBV) are hypothesized in the etiopathogenesis of multiple sclerosis (MS). This study investigated if HHV‐6A and EBV seroreactivities interact regarding the risk of developing MS. Antibodies against viral antigens were analyzed in biobank samples from 670 individuals who later developed MS and matched controls. Additive interactions were analyzed. A significant interaction between HHV‐6A and EBNA‐1 seroreactivities was observed in study participants above the median age of 24.9 years (attributable proportion due to interaction = 0.45). This finding supports the hypothesis that HHV‐6A and EBV infections interact in MS development. ANN NEUROL 2024;96:302–305
- Open Access
- 22 November 2022
- Published by SAGE Publications in Multiple Sclerosis Journal – Experimental, Translational and Clinical
- Vol. 8 (4)
Systemic inflammation and risk of multiple sclerosis – A presymptomatic case-control study
Background: C-reactive protein (CRP) is a marker of systemic inflammation. Increased levels of CRP in young persons have been suggested to decrease the risk of multiple sclerosis (MS). Objectives: To assess CRP as a risk factor for MS. Methods: Levels of CRP were measured with a high-sensitive immunoassay in biobank samples from 837 individuals who later developed MS and 984 matched controls. The risk of developing MS was analysed by conditional logistic regression on z-scored CRP values. Results: Levels of CRP were not associated with MS risk. Conclusions: We found no association between CRP levels and risk of MS development.
- 22 November 2022
- Published by SAGE Publications in Multiple Sclerosis Journal – Experimental, Translational and Clinical
- Vol. 8 (4)
Open AccessSystemic inflammation and risk of multiple sclerosis – A presymptomatic case-control study
Background: C-reactive protein (CRP) is a marker of systemic inflammation. Increased levels of CRP in young persons have been suggested to decrease the risk of multiple sclerosis (MS). Objectives: To assess CRP as a risk factor for MS. Methods: Levels of CRP were measured with a high-sensitive immunoassay in biobank samples from 837 individuals who later developed MS and 984 matched controls. The risk of developing MS was analysed by conditional logistic regression on z-scored CRP values. Results: Levels of CRP were not associated with MS risk. Conclusions: We found no association between CRP levels and risk of MS development.
- Open Access
- 4 June 2022
- Published by Wiley in European Journal of Neurology
- Vol. 29 (8) , 2335-2342
Free vitamin D3 index and vitamin D‐binding protein in multiple sclerosis: A presymptomatic case–control study
Background and purpose High levels of 25-hydroxyvitamin D-3 (25[OH]D-3) are associated with a lower risk for multiple sclerosis (MS). The bioavailability of 25(OH)D-3 is regulated by its main plasma carrier, vitamin D-binding protein (DBP). Free 25(OH)D-3 can be estimated by also measuring DBP concentration. In addition, DBP has immunomodulatory functions that may independently affect MS pathogenesis. No previous studies have assessed free 25(OH)D-3 or DBP in presymptomatically collected samples. This study was undertaken to assess free 25(OH)D-3 and DBP as risk factors for MS. Methods A nested case-control study was performed with presymptomatic serum samples identified through cross-linkage of MS registries and Swedish biobanks. Concentration of 25(OH)D-3 was measured with liquid chromatography and DBP levels with sandwich immunoassay. Free 25(OH)D-3 was approximated as free vitamin D-3 index: (25[OH]D-3/DBP) x 10(3). MS risk was analyzed by conditional logistic regression, calculating odds ratios (ORs) with 95% confidence intervals (CIs). Results Serum samples from 660 pairs of matched cases and controls were included. At <20 years of age, high levels of free vitamin D-3 index were associated with a lower risk of MS (highest vs. lowest quintile: OR = 0.37, 95% CI = 0.15-0.91, p for trend across quintiles = 0.04). At age 30-39 years, high levels of DBP were associated with a lower MS risk (highest vs. lowest quintile: OR = 0.36, 95% CI = 0.15-0.85, p for trend = 0.02). Conclusions These findings support the hypothesis that high levels of free 25(OH)D-3 at a young age reduce the risk of MS later in life. They also implicate a role for DBP in MS etiology.
- 4 June 2022
- Published by Wiley in European Journal of Neurology
- Vol. 29 (8) , 2335-2342
Open AccessFree vitamin D3 index and vitamin D‐binding protein in multiple sclerosis: A presymptomatic case–control study
Background and purpose High levels of 25-hydroxyvitamin D-3 (25[OH]D-3) are associated with a lower risk for multiple sclerosis (MS). The bioavailability of 25(OH)D-3 is regulated by its main plasma carrier, vitamin D-binding protein (DBP). Free 25(OH)D-3 can be estimated by also measuring DBP concentration. In addition, DBP has immunomodulatory functions that may independently affect MS pathogenesis. No previous studies have assessed free 25(OH)D-3 or DBP in presymptomatically collected samples. This study was undertaken to assess free 25(OH)D-3 and DBP as risk factors for MS. Methods A nested case-control study was performed with presymptomatic serum samples identified through cross-linkage of MS registries and Swedish biobanks. Concentration of 25(OH)D-3 was measured with liquid chromatography and DBP levels with sandwich immunoassay. Free 25(OH)D-3 was approximated as free vitamin D-3 index: (25[OH]D-3/DBP) x 10(3). MS risk was analyzed by conditional logistic regression, calculating odds ratios (ORs) with 95% confidence intervals (CIs). Results Serum samples from 660 pairs of matched cases and controls were included. At <20 years of age, high levels of free vitamin D-3 index were associated with a lower risk of MS (highest vs. lowest quintile: OR = 0.37, 95% CI = 0.15-0.91, p for trend across quintiles = 0.04). At age 30-39 years, high levels of DBP were associated with a lower MS risk (highest vs. lowest quintile: OR = 0.36, 95% CI = 0.15-0.85, p for trend = 0.02). Conclusions These findings support the hypothesis that high levels of free 25(OH)D-3 at a young age reduce the risk of MS later in life. They also implicate a role for DBP in MS etiology.
- Open Access
- 3 May 2022
- Published by Wiley in Annals of Clinical and Translational Neurology
- Vol. 9 (6) , 882-887
Axonal injury in asymptomatic individuals preceding onset of multiple sclerosis
Axonal loss is the main cause of irreversible disability in multiple sclerosis (MS). Serum neurofilament light (sNfL) is a biomarker of axonal disintegration. In this nested case–control study, blood samples from 519 presymptomatic persons (age range 4–39 years) who later received an MS diagnosis showed higher sNfL concentrations than 519 matched controls (p < 0.0001), noticeable at least 10 years before clinical MS onset. Mean values for pre‐MS and control groups were 9.6 pg/mL versus 7.4 pg/mL 0–5 years before onset, and 6.4 pg/mL versus 5.8 pg/mL 5–10 years before onset. These results support that axonal injury occurs early in MS pathogenesis.
- 3 May 2022
- Published by Wiley in Annals of Clinical and Translational Neurology
- Vol. 9 (6) , 882-887
Open AccessAxonal injury in asymptomatic individuals preceding onset of multiple sclerosis
Axonal loss is the main cause of irreversible disability in multiple sclerosis (MS). Serum neurofilament light (sNfL) is a biomarker of axonal disintegration. In this nested case–control study, blood samples from 519 presymptomatic persons (age range 4–39 years) who later received an MS diagnosis showed higher sNfL concentrations than 519 matched controls (p < 0.0001), noticeable at least 10 years before clinical MS onset. Mean values for pre‐MS and control groups were 9.6 pg/mL versus 7.4 pg/mL 0–5 years before onset, and 6.4 pg/mL versus 5.8 pg/mL 5–10 years before onset. These results support that axonal injury occurs early in MS pathogenesis.
- Open Access
- 9 June 2021
- Published by Wiley in European Journal of Neurology
- Vol. 28 (9) , 3072-3079
Cytomegalovirus seropositivity is associated with reduced risk of multiple sclerosis—a presymptomatic case–control study
Background and purpose: Epstein–Barr virus (EBV) and human herpesvirus 6A (HHV‐6A) are associated with increased risk of multiple sclerosis (MS). Conversely, infection with cytomegalovirus (CMV) has been suggested to reduce the risk of MS but supporting data from presymptomatic studies are lacking. Here, it was sought to increase the understanding of CMV in MS aetiology.Methods: A nested case–control study was performed with presymptomatically collected blood samples identified through crosslinkage of MS registries and Swedish biobanks. Serological antibody response against CMV, EBV and HHV‐6A was determined using a bead‐based multiplex assay. Odds ratio (OR) with 95% confidence interval (CI) for CMV seropositivity as a risk factor for MS was calculated by conditional logistic regression and adjusted for EBV and HHV‐6A seropositivity. Potential interactions on the additive scale were analysed by calculating the attributable proportion due to interaction (AP).Results: Serum samples from 670 pairs of matched cases and controls were included. CMV seropositivity was associated with a reduced risk for MS (OR = 0.70, 95% CI 0.56–0.88, p = 0.003). Statistical interactions on the additive scale were observed between seronegativity for CMV and seropositivity against HHV‐6A (AP 0.34, 95% CI 0.06–0.61) and EBV antigen EBNA‐1 (amino acid 385–420) at age 20–39 years (AP 0.37, 95% CI 0.09–0.65).Conclusions: Cytomegalovirus seropositivity is associated with a decreased risk for MS. The protective role for CMV infection in MS aetiology is further supported by the interactions between CMV seronegativity and EBV and HHV‐6A seropositivity.
- 9 June 2021
- Published by Wiley in European Journal of Neurology
- Vol. 28 (9) , 3072-3079
Open AccessCytomegalovirus seropositivity is associated with reduced risk of multiple sclerosis—a presymptomatic case–control study
Background and purpose: Epstein–Barr virus (EBV) and human herpesvirus 6A (HHV‐6A) are associated with increased risk of multiple sclerosis (MS). Conversely, infection with cytomegalovirus (CMV) has been suggested to reduce the risk of MS but supporting data from presymptomatic studies are lacking. Here, it was sought to increase the understanding of CMV in MS aetiology.Methods: A nested case–control study was performed with presymptomatically collected blood samples identified through crosslinkage of MS registries and Swedish biobanks. Serological antibody response against CMV, EBV and HHV‐6A was determined using a bead‐based multiplex assay. Odds ratio (OR) with 95% confidence interval (CI) for CMV seropositivity as a risk factor for MS was calculated by conditional logistic regression and adjusted for EBV and HHV‐6A seropositivity. Potential interactions on the additive scale were analysed by calculating the attributable proportion due to interaction (AP).Results: Serum samples from 670 pairs of matched cases and controls were included. CMV seropositivity was associated with a reduced risk for MS (OR = 0.70, 95% CI 0.56–0.88, p = 0.003). Statistical interactions on the additive scale were observed between seronegativity for CMV and seropositivity against HHV‐6A (AP 0.34, 95% CI 0.06–0.61) and EBV antigen EBNA‐1 (amino acid 385–420) at age 20–39 years (AP 0.37, 95% CI 0.09–0.65).Conclusions: Cytomegalovirus seropositivity is associated with a decreased risk for MS. The protective role for CMV infection in MS aetiology is further supported by the interactions between CMV seronegativity and EBV and HHV‐6A seropositivity.
- Open Access
- 16 October 2020
- Published by Wiley in European Journal of Neurology
- Vol. 28 (2) , 579-586
Epstein–Barr virus infection after adolescence and human herpesvirus 6A as risk factors for multiple sclerosis
Background and purpose: Infections with human herpesvirus 6A (HHV‐6A) and Epstein–Barr virus (EBV) have been linked to multiple sclerosis (MS) development. For EBV, late infection has been proposed as a risk factor, but serological support is lacking. The objective of this study was to investigate how age affects the EBV and HHV‐6A associated risks of developing MS.Methods: In this nested case–control study, Swedish biobanks were accessed to find pre‐symptomatically collected blood samples from 670 individuals who later developed relapsing MS and 670 matched controls. A bead‐based multiplex assay was used to determine serological response against EBV and HHV‐6A. Conditional logistic regression was used to calculate odds ratios and 95% confidence intervals.Results: Seropositivity against EBV exhibited a pattern where associations switched from a decreased risk of developing MS in the group below 20 years of age to an increased risk amongst individuals aged 20–29 and 30–39 years (p for trend 0.020). The age of transition was estimated to be 18.8 years. In contrast, HHV‐6A was associated with increased MS risk in all age groups (total cohort odds ratio 2.1, 95% confidence interval 1.6–2.7).Conclusions: This study suggests EBV infection after adolescence and age independent HHV‐6A infection as risk factors for MS.
- 16 October 2020
- Published by Wiley in European Journal of Neurology
- Vol. 28 (2) , 579-586
Open AccessEpstein–Barr virus infection after adolescence and human herpesvirus 6A as risk factors for multiple sclerosis
Background and purpose: Infections with human herpesvirus 6A (HHV‐6A) and Epstein–Barr virus (EBV) have been linked to multiple sclerosis (MS) development. For EBV, late infection has been proposed as a risk factor, but serological support is lacking. The objective of this study was to investigate how age affects the EBV and HHV‐6A associated risks of developing MS.Methods: In this nested case–control study, Swedish biobanks were accessed to find pre‐symptomatically collected blood samples from 670 individuals who later developed relapsing MS and 670 matched controls. A bead‐based multiplex assay was used to determine serological response against EBV and HHV‐6A. Conditional logistic regression was used to calculate odds ratios and 95% confidence intervals.Results: Seropositivity against EBV exhibited a pattern where associations switched from a decreased risk of developing MS in the group below 20 years of age to an increased risk amongst individuals aged 20–29 and 30–39 years (p for trend 0.020). The age of transition was estimated to be 18.8 years. In contrast, HHV‐6A was associated with increased MS risk in all age groups (total cohort odds ratio 2.1, 95% confidence interval 1.6–2.7).Conclusions: This study suggests EBV infection after adolescence and age independent HHV‐6A infection as risk factors for MS.
- Open Access
- 14 July 2020
- Published by SAGE Publications in Multiple Sclerosis Journal
- Vol. 27 (1) , 161-162
Response to ‘Mendelian randomization analysis does not support a role for leptin in multiple sclerosis’
- 14 July 2020
- Published by SAGE Publications in Multiple Sclerosis Journal
- Vol. 27 (1) , 161-162
Open AccessResponse to ‘Mendelian randomization analysis does not support a role for leptin in multiple sclerosis’
- Open Access
- 7 February 2020
- Published by SAGE Publications in Multiple Sclerosis Journal
- Vol. 27 (1) , 19-27
Leptin levels are associated with multiple sclerosis risk
Obesity early in life has been linked to increased risk of developing multiple sclerosis (MS). Leptin and insulin are both associated with obesity, making them suitable candidates for investigating this connection. To determine if leptin and insulin are risk factors for relapsing–remitting multiple sclerosis (RRMS). In this nested case–control study using blood samples from Swedish biobanks, we compared concentrations of leptin and insulin in 649 individuals who later developed RRMS with 649 controls matched for biobank, sex, age and date of sampling. Only pre-symptomatically drawn samples from individuals below the age of 40 years were included. Conditional logistic regression was performed on z-scored values to calculate odds ratios (ORs) with 95% confidence intervals (CIs). A 1-unit leptin z-score increase was associated with increased risk of MS in individuals younger than 20 years (OR = 1.4, 95% CI = 1.1–1.9) and in all men (OR = 1.4, 95% CI = 1.0–2.0). In contrast, for women aged 30–39 years, there was a lower risk of MS with increased leptin levels (OR = 0.74, 95% CI = 0.54–1.0) when adjusting for insulin levels. We show that the pro-inflammatory adipokine leptin is a risk factor for MS among young individuals.
- 7 February 2020
- Published by SAGE Publications in Multiple Sclerosis Journal
- Vol. 27 (1) , 19-27
Open AccessLeptin levels are associated with multiple sclerosis risk
Obesity early in life has been linked to increased risk of developing multiple sclerosis (MS). Leptin and insulin are both associated with obesity, making them suitable candidates for investigating this connection. To determine if leptin and insulin are risk factors for relapsing–remitting multiple sclerosis (RRMS). In this nested case–control study using blood samples from Swedish biobanks, we compared concentrations of leptin and insulin in 649 individuals who later developed RRMS with 649 controls matched for biobank, sex, age and date of sampling. Only pre-symptomatically drawn samples from individuals below the age of 40 years were included. Conditional logistic regression was performed on z-scored values to calculate odds ratios (ORs) with 95% confidence intervals (CIs). A 1-unit leptin z-score increase was associated with increased risk of MS in individuals younger than 20 years (OR = 1.4, 95% CI = 1.1–1.9) and in all men (OR = 1.4, 95% CI = 1.0–2.0). In contrast, for women aged 30–39 years, there was a lower risk of MS with increased leptin levels (OR = 0.74, 95% CI = 0.54–1.0) when adjusting for insulin levels. We show that the pro-inflammatory adipokine leptin is a risk factor for MS among young individuals.